291 related articles for article (PubMed ID: 28466469)
21. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.
Solomon SR; Aubrey MT; Zhang X; Piluso A; Freed BM; Brown S; Jackson KC; Morris LE; Holland HK; Solh MM; Bashey A
Biol Blood Marrow Transplant; 2018 Apr; 24(4):789-798. PubMed ID: 29355721
[TBL] [Abstract][Full Text] [Related]
22. Donor Selection Based on Killer Cell Immunoglobulin-Like Receptor (KIR) Genotype May Improve Outcome After T-Cell-Replete Haploidentical Transplantation.
Torío A; Pascual MJ; Vidales I; Ortiz M; Caballero A; Heiniger AI
Transplant Proc; 2018 Mar; 50(2):679-682. PubMed ID: 29579887
[TBL] [Abstract][Full Text] [Related]
23. Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor.
Behrendt CE; Nakamura R; Forman SJ; Zaia JA
Front Immunol; 2013; 4():36. PubMed ID: 23440333
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation.
Bastos-Oreiro M; Anguita J; Martínez-Laperche C; Fernández L; Buces E; Navarro A; Pascual C; Pérez-Corral A; Balsalobre P; Muñoz C; Kwon M; Serrano D; Perez-Martinez A; Buño I; Gayoso J; Díez-Martín JL
Eur J Haematol; 2016 May; 96(5):483-91. PubMed ID: 26133015
[TBL] [Abstract][Full Text] [Related]
25. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.
Michaelis SU; Mezger M; Bornhäuser M; Trenschel R; Stuhler G; Federmann B; Oevermann L; Kanz L; Handgretinger R; Bethge WA
Ann Hematol; 2014 Sep; 93(9):1579-86. PubMed ID: 24771045
[TBL] [Abstract][Full Text] [Related]
26. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
[TBL] [Abstract][Full Text] [Related]
27. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
28. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?
Willemze R; Ruggeri A; Purtill D; Rodrigues CA; Gluckman E; Rocha V;
Best Pract Res Clin Haematol; 2010 Jun; 23(2):283-90. PubMed ID: 20837340
[TBL] [Abstract][Full Text] [Related]
29. Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort.
Glushkova S; Shelikhova L; Voronin K; Pershin D; Vedmedskaya V; Muzalevskii Y; Kazachenok A; Kurnikova E; Radygina S; Ilushina M; Khismatullina R; Maschan A; Maschan M
Transplant Cell Ther; 2024 Apr; 30(4):435.e1-435.e12. PubMed ID: 38278183
[TBL] [Abstract][Full Text] [Related]
30. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation.
Yabe T; Matsuo K; Hirayasu K; Kashiwase K; Kawamura-Ishii S; Tanaka H; Ogawa A; Takanashi M; Satake M; Nakajima K; Tokunaga K; Inoko H; Saji H; Ogawa S; Juji T; Sasazuki T; Kodera Y; Morishima Y;
Biol Blood Marrow Transplant; 2008 Jan; 14(1):75-87. PubMed ID: 18158964
[TBL] [Abstract][Full Text] [Related]
31. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
32. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
[TBL] [Abstract][Full Text] [Related]
33. Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.
Litjens NHR; van der Wagen L; Kuball J; Kwekkeboom J
Front Immunol; 2018; 9():389. PubMed ID: 29545802
[TBL] [Abstract][Full Text] [Related]
34. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies.
Cardozo DM; Marangon AV; da Silva RF; Aranha FJP; Visentainer JEL; Bonon SHA; Costa SCB; Miranda ECM; de Souza CA; Guimarães F
Hum Immunol; 2016 Oct; 77(10):861-868. PubMed ID: 27394130
[TBL] [Abstract][Full Text] [Related]
36. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
37. Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies.
Muccio L; Bertaina A; Falco M; Pende D; Meazza R; Lopez-Botet M; Moretta L; Locatelli F; Moretta A; Della Chiesa M
Haematologica; 2016 Mar; 101(3):371-81. PubMed ID: 26659918
[TBL] [Abstract][Full Text] [Related]
38. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
39. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
40. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.
Koenecke C; Shaffer J; Alexander SI; Preffer F; Dombkowski D; Saidman SL; Dey B; McAfee S; Spitzer TR; Sykes M
Exp Hematol; 2003 Oct; 31(10):911-23. PubMed ID: 14550807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
